Thrombin-stimulated connective tissue growth factor (CTGF/CCN2) production in human buccal mucosal fibroblasts: Inhibition by epigallocatechin-3-gallate

Head and Neck

Volumn 34, Issue 8, 2012, Pages 1089-1094

  Chang, Jenny Zwei Chieng ^a   Yang, Wan Hsien ^a   Deng, Yi Ting ^a   Chen, Hsin Ming ^a   Kuo, Mark Yen Ping ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

CCN2; chemoprevention; EGCG; oral submucous fibrosis; thrombin

Indexed keywords

ACETYLCYSTEINE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTIOXIDANT; APOPTOSIS SIGNAL REGULATING KINASE 1; CONNECTIVE TISSUE GROWTH FACTOR; ENZYME INHIBITOR; EPIGALLOCATECHIN GALLATE; PROTEINASE ACTIVATED RECEPTOR 1; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; THIOREDOXIN; THROMBIN;

APOPTOSIS; ARTICLE; BUCCAL MUCOSAL FIBROBLAST; FIBROBLAST; HUMAN; HUMAN CELL; INJURY; MOUTH DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

AMINO ACID CHLOROMETHYL KETONES; ANTICARCINOGENIC AGENTS; ARECA; BLOTTING, WESTERN; CATECHIN; CELLS, CULTURED; CONNECTIVE TISSUE GROWTH FACTOR; FIBROBLASTS; HEMOSTATICS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE KINASE KINASE 5; MASTICATION; MOUTH MUCOSA; ORAL SUBMUCOUS FIBROSIS; REACTIVE OXYGEN SPECIES; RECEPTOR, PAR-1; SERINE PROTEINASE INHIBITORS; THROMBIN; UP-REGULATION;

EID: 84864278101     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21863     Document Type: Article

References (40)

1. Yanjia H, Xinchun J,. The role of epithelial-mesenchymal transition in oral squamous cell carcinoma and oral submucous fibrosis. Clin Chim Acta 2007; 383: 51-56.
2. Tilakaratne WM, Klinikowski MF, Saku T, Peters TJ, Warnakulasuriya S,. Oral submucous fibrosis: review on aetiology and pathogenesis. Oral Oncol 2006; 42: 561-568.
3. Rajalalitha P, Vali S,. Molecular pathogenesis of oral submucous fibrosis-a collagen metabolic disorder. J Oral Pathol Med 2005; 34: 321-328.
4. Angadi PV, Rao SS,. Areca nut in pathogenesis of oral submucous fibrosis: revisited. Oral Maxillofac Surg 2011; 15: 1-9.
5. Moutasim KA, Jenei V, Sapienza K, et al. Betel-derived alkaloid up-regulates keratinocyte alphavbeta6 integrin expression and promotes oral submucous fibrosis. J Pathol 2011; 223: 366-377.
6. Chiang CP, Hsieh RP, Chen TH, et al. High incidence of autoantibodies in Taiwanese patients with oral submucous fibrosis. J Oral Pathol Med 2002; 31: 402-409.
7. Phatak AG,. Oral submucous fibrosis. BMJ 1995; 310: 871.
8. Rajendran R,. Oral submucous fibrosis: etiology, pathogenesis, and future research. Bull World Health Organ 1994; 72: 985-996.
9. Mitroulis I, Kambas K, Anyfanti P, Doumas M, Ritis K,. The multivalent activity of the tissue factor-thrombin pathway in thrombotic and non-thrombotic disorders as a target for therapeutic intervention. Expert Opin Ther Targets 2010; 15: 75-89.
10. Wynn TA,. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 2007; 117: 524-529.
11. Licari LG, Kovacic JP,. Thrombin physiology and pathophysiology. J Vet Emerg Crit Care (San Antonio) 2009; 19: 11-22.
12. Coughlin SR,. Thrombin signalling and protease-activated receptors. Nature 2000; 407: 258-264.
13. Bogatkevich GS, Tourkina E, Silver RM, Ludwicka-Bradley A,. Thrombin differentiates normal lung fibroblasts to a myofibroblast phenotype via the proteolytically activated receptor-1 and a protein kinase C-dependent pathway. J Biol Chem 2001; 276: 45184-45192.
14. Chambers RC, Leoni P, Blanc-Brude OP, Wembridge DE, Laurent GJ,. Thrombin is a potent inducer of connective tissue growth factor production via proteolytic activation of protease-activated receptor-1. J Biol Chem 2000; 275: 35584-35591.
15. Leask A,. Thrombin-induced CCN2 expression as a target for anti-fibrotic therapy in scleroderma. J Cell Commun Signal 2010; 4: 111-112.
16. Howell DC, Goldsack NR, Marshall RP, et al. Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis. Am J Pathol 2001; 159: 1383-1395.
17. Bogatkevich GS, Ludwicka-Bradley A, Silver RM,. Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts. Arthritis Rheum 2009; 60: 3455-3464.
18. Leask A, Sa S, Holmes A, Shiwen X, Black CM, Abraham DJ,. The control of ccn2 (ctgf) gene expression in normal and scleroderma fibroblasts. Mol Pathol 2001; 54: 180-183.
19. Kantarci A, Black S, Xydas C, et al. Epithelial and connective tissue cell CTGF/CCN2 expression in gingival fibrosis. J Pathol 2006; 210: 59-66.
20. Paradis V, Dargere D, Vidaud M, et al. Expression of connective tissue growth factor in experimental rat and human liver fibrosis. Hepatology 1999; 30: 968-976.
21. Allen JT, Knight RA, Bloor CA, Spiteri MA,. Enhanced insulin-like growth factor binding protein-related protein 2 (Connective tissue growth factor) expression in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Cell Mol Biol 1999; 21: 693-700.
22. Ito Y, Aten J, Bende RJ, et al. Expression of connective tissue growth factor in human renal fibrosis. Kidney Int 1998; 53: 853-861.
23. Brigstock DR,. Connective tissue growth factor (CCN2, CTGF) and organ fibrosis: lessons from transgenic animals. J Cell Commun Signal 2010; 4: 1-4.
24. Shi-Wen X, Stanton LA, Kennedy L, et al. CCN2 is necessary for adhesive responses to transforming growth factor-beta1 in embryonic fibroblasts. J Biol Chem 2006; 281: 10715-10726.
25. Holmes A, Abraham DJ, Sa S, Shiwen X, Black CM, Leask A,. CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem 2001; 276: 10594-10601.
26. Deng YT, Chen HM, Cheng SJ, Chiang CP, Kuo MY,. Arecoline-stimulated connective tissue growth factor production in human buccal mucosal fibroblasts: modulation by curcumin. Oral Oncol 2009; 45: e99-e105.
27. Chan CP, Chang MC, Wang YJ, et al. Thrombin activates Ras-CREB/ATF-1 signaling and stimulates c-fos, c-jun, and c-myc expression in human gingival fibroblasts. J Periodontol 2008; 79: 1248-1254.
28. Black SA, Jr., Palamakumbura AH, Stan M, Trackman PC,. Tissue-specific mechanisms for CCN2/CTGF persistence in fibrotic gingiva: interactions between cAMP and MAPK signaling pathways, and prostaglandin E2-EP3 receptor mediated activation of the c-JUN N-terminal kinase. J Biol Chem 2007; 282: 15416-15429.
29. Yu CC, Hsu MJ, Kuo ML, et al. Thrombin-induced connective tissue growth factor expression in human lung fibroblasts requires the ASK1/JNK/AP-1 pathway. J Immunol 2009; 182: 7916-7927.
30. Wang HJ, Lo WY, Lu TL, Huang H,. (-)-Epigallocatechin-3-gallate decreases thrombin/paclitaxel-induced endothelial tissue factor expression via the inhibition of c-Jun terminal NH2 kinase phosphorylation. Biochem Biophys Res Commun. 2010; 391: 716-721.
31. Carney DH, Herbosa GJ, Stiernberg J, et al. Double-signal hypothesis for thrombin initiation of cell proliferation. Semin Thromb Hemost 1986; 12: 231-240.
32. Fager G,. Thrombin and proliferation of vascular smooth muscle cells. Circ Res 1995; 77: 645-650.
33. Dawes KE, Gray AJ, Laurent GJ,. Thrombin stimulates fibroblast chemotaxis and replication. Eur J Cell Biol 1993; 61: 126-130.
34. Steinhoff M, Buddenkotte J, Shpacovitch V, et al. Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev 2005; 26: 1-43.
35. Hattori K, Naguro I, Runchel C, Ichijo H,. The roles of ASK family proteins in stress responses and diseases. Cell Commun Signal 2009; 7: 9.
36. Cabrera C, Artacho R, Gimenez R,. Beneficial effects of green tea-a review. J Am Coll Nutr 2006; 25: 79-99.
37. Tipoe GL, Leung TM, Liong EC, Lau TY, Fung ML, Nanji AA,. Epigallocatechin-3-gallate (EGCG) reduces liver inflammation, oxidative stress and fibrosis in carbon tetrachloride (CCl4)-induced liver injury in mice. Toxicology 2010; 273: 45-52.
38. Sriram N, Kalayarasan S, Sudhandiran G,. Epigallocatechin-3-gallate augments antioxidant activities and inhibits inflammation during bleomycin-induced experimental pulmonary fibrosis through Nrf2-Keap1 signaling. Pulm Pharmacol Ther 2009; 22: 221-236.
39. Hao J, Kim CH, Ha TS, Ahn HY,. Epigallocatechin-3 gallate prevents cardiac hypertrophy induced by pressure overload in rats. J Vet Sci 2007; 8: 121-129.
40. Wang HJ, Lo WY, Lu TL, Huang H,. (-)Epigallocatechin-3-gallate decreases thrombin/paclitaxel-induced endothelial tissue factor expression via the inhibition of c-Jun terminal NH2 kinase phosphorylation. Biochem Biophys Res Commun 2010; 39: 716-721.